title: Evaluation of positive inotropic drug effects on thyroid hormone levels after open heart surgery.
abstract: OBJECTIVE
  The aim of this study was to examine the effects of positive inotropic drugs, including adrenaline, dopamine, and dobutamine on thyroid hormone levels following open heart surgery.
  
  
  METHODS
  We analyzed free thyroid hormones (FT3 and FT4) and thyroid-stimulating hormones (TSH) in 200 consecutive patients undergoing open heart surgery. Patients were divided into 5 groups according to the inotropic drug administration as follows: Group A (n = 46) received dopamine alone; Group B (n = 40), dopamine and dobutamine; Group C (n = 36), dopamine, dobutamine, and adrenaline; Group D (n = 32), adrenaline alone; and Group E (n = 46), placebo. Procedural factors affecting thyroid hormones were recorded and included cardiopulmonary bypass (CPB) time, cross-clamping time, degree of hypothermia, and the duration and doses of positive inotropic drugs. Blood samples for hormone assays were collected before initiation of inotropic drug therapy (baseline) and postoperatively at 24, 72, and 120 hours after drug therapy.
  
  
  RESULTS
  FT3, FT4, and TSH levels at baseline were similar in all groups. Although there was a trend showing very slight increases in thyroid hormone levels from baseline to the 24th, 72nd, and 120th postoperative hours after drug therapy, these changes were not significant, and there were also no significant differences between the groups. There was also no significant statistical difference in CPB time, cross-clamping time, degree of hypothermia, and duration and doses of positive inotropic drugs between groups.
  
  
  CONCLUSIONS
  Although thyroid hormone levels were affected by positive inotropic drug usage after open heart surgery, this effect was not significant and thyroid hormone levels remained within normal ranges.
authors.affiliation: Department of Cardiovascular Surgery, Yuksek Ihtisas Hospital of Turkey, Ankara, Turkey. drukervan@yahoo.com
authors.forename: Umit
authors.initials: U
authors.lastname: Kervan
authors.forename: Anil
authors.initials: A
authors.lastname: Ozen
authors.forename: Utku
authors.initials: U
authors.lastname: Unal
authors.forename: Irfan
authors.initials: I
authors.lastname: Tasoglu
authors.forename: Mahmut Mustafa
authors.initials: MM
authors.lastname: Ulas
authors.forename: Kumral
authors.initials: K
authors.lastname: Cagli
authors.forename: Alper
authors.initials: A
authors.lastname: Uzun
authors.forename: Hasmet
authors.initials: H
authors.lastname: Bardakci
authors.forename: Kerim
authors.initials: K
authors.lastname: Cagli
mesh_terms: D002316:Cardiotonic Agents / Q000627:therapeutic use*; D013504:Cardiovascular Surgical Procedures / Q000706:statistics & numerical data*; D005067:Euthyroid Sick Syndromes / Q000097:blood* / Q000453:epidemiology* / Q000517:prevention & control; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000097:blood* / Q000453:epidemiology* / Q000517:prevention & control; D015995:Prevalence; D018570:Risk Assessment; D013903:Thoracic Surgery / Q000706:statistics & numerical data; D013963:Thyroid Hormones / Q000097:blood*; D016896:Treatment Outcome; D014421:Turkey / Q000453:epidemiology
chemical_list: D002316:Cardiotonic Agents; D013963:Thyroid Hormones